Refine
Has Fulltext
- yes (207)
Is part of the Bibliography
- yes (207)
Year of publication
Document Type
- Journal article (184)
- Doctoral Thesis (22)
- Review (1)
Language
- English (207) (remove)
Keywords
- NFATc1 (13)
- CXCR4 (7)
- apoptosis (7)
- T cells (6)
- glioblastoma (6)
- immunohistochemistry (6)
- lymphoma (6)
- multiple myeloma (6)
- B cells (5)
- Transkriptionsfaktor (5)
- astrocytoma (5)
- cancer (5)
- gene expression (5)
- glioblastoma multiforme (5)
- recurrence (5)
- NFAT (4)
- brain (4)
- breast cancer (4)
- chemokine receptor (4)
- expression (4)
- forensic neuropathology (4)
- gene regulation (4)
- mRNA (4)
- machine learning (4)
- metastasis (4)
- prognosis (4)
- relapse (4)
- therapy (4)
- Apoptosis (3)
- EGFR (3)
- Hodgkin lymphoma (3)
- MYC (3)
- Medizin (3)
- NRF2 (3)
- PET/CT (3)
- Proliferation (3)
- biomarker (3)
- cerebrospinal fluid (3)
- forensic neurotraumatology (3)
- germinal center (3)
- glioma (3)
- melanoma (3)
- neuronal differentiation (3)
- poor prognosis (3)
- positron emission tomography (3)
- protein (3)
- surgical oncology (3)
- thymus (3)
- ATF4 (2)
- B-Lymphozyten (2)
- BCL6 (2)
- CD30 (2)
- CRISPR/Cas9 (2)
- Cushing’s syndrome (2)
- DLBCL (2)
- EMT (2)
- Expression (2)
- FGFR (2)
- Glioblastoma (2)
- Graft-versus-leukemia (2)
- HNSCC (2)
- KEAP1 (2)
- Lymphom (2)
- Lymphoma (2)
- Lymphozyten (2)
- MPS1 (2)
- Maus (2)
- Microarray (2)
- Multiple Myeloma (2)
- NAFLD (2)
- NASH (2)
- NSCLC (2)
- Nfatc1 (2)
- PET (2)
- PTCL (2)
- Rhabdomyosarcoma (2)
- T-Lymphozyt (2)
- T-cell lymphoma (2)
- USP28 (2)
- adrenocortical carcinoma (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- angiogenesis (2)
- animal model (2)
- antigen (2)
- brain tumor (2)
- cancer stem cells (2)
- cancers and neoplasms (2)
- carcinomas (2)
- case report (2)
- cell staining (2)
- cell-cycle arrest (2)
- cytotoxic T cells (2)
- development (2)
- discriminant analysis (2)
- endothelial cells (2)
- enzyme-linked immunoassays (2)
- flow cytometry (2)
- gene (2)
- imaging (2)
- immune response (2)
- immunohistochemistry techniques (2)
- in vivo imaging (2)
- inflammation (2)
- keratinocytes (2)
- kidneys (2)
- low-grade glioma (2)
- lung cancer (2)
- malignant tumors (2)
- messenger RNA (2)
- miRNA (2)
- mice (2)
- microenvironment (2)
- molecular diagnostics (2)
- molecular imaging (2)
- mouse models (2)
- mutations (2)
- neuroinflammation (2)
- obesity (2)
- organoids (2)
- plasma cells (2)
- positron emission tomography/computed tomography (2)
- postnatal development (2)
- principal component analysis (2)
- proteomics (2)
- rat (2)
- receptor tyrosine kinases (2)
- regression analysis (2)
- survival (2)
- temozolomide (2)
- transcription (2)
- tumor microenvironment (2)
- vestibular schwannoma (2)
- vitamin D (2)
- 3D ex vivo models (1)
- 3D lung tumor tissue models (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AD-AID (1)
- ADAM9 (1)
- ADP-ribosylation toxins (1)
- AICDA (1)
- AID-ΔE4a (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- ATG7 (1)
- ATM (1)
- Activation (1)
- Activation induced cell death/AICD (1)
- Adamantiades-Behçet disease (1)
- Adult (1)
- Allogenic hematopoietic stem cell transplantation (1)
- Alpha therapy (1)
- Amplicon Sequencing (1)
- Anergy (1)
- Antibodies (1)
- Antigen (1)
- Antigen CD8 (1)
- Antiparanodal Autoantibodies (1)
- Aphthae (1)
- Autoantikörper (1)
- Autoimmune diseases (1)
- Autoregulation (1)
- B Lymphocytes (1)
- B cell malignancies (1)
- B-Lymphozyt (1)
- B-MYB (1)
- B-Zell-Leukämie (1)
- B-cell lymphoma (1)
- B-cells (1)
- B-lymphocytes (1)
- BCL2 (1)
- BIRC7 (1)
- Barrett-Ösophagus (1)
- Bauchfellentzündung (1)
- Behçet’s disease (1)
- Bevacizumab (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Blimp-1 (1)
- Bone chips (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- Braak (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- Burkitt (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- C3 (1)
- CD/metabolism (1)
- CD117 (1)
- CD133 (1)
- CD274 (1)
- CD319 (1)
- CD40 ligand (1)
- CD56 (1)
- CD8 (1)
- CD9 (1)
- CHAC1 (1)
- CK5 (1)
- COVID-19 (1)
- CRC (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas-Methode (1)
- CS1 (1)
- CSF (1)
- CTL function (1)
- CTNNB1 (1)
- CX5461 (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- CXCR4/SDF-1 (1)
- CXCR5 (1)
- CXCR7 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Calcineurin (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Cartilage Oligomeric Matrix Protein (1)
- Caspase 12 (1)
- Ccl2 (1)
- Chains (1)
- Chemotherapy (1)
- Childhood (1)
- Cisplatin (1)
- Clonality (1)
- Clonality analysis (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- Cytotoxizität (1)
- DEL(5Q) (1)
- DHAP (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- DNA-PK (1)
- DOTATOC (1)
- DT40 cells (1)
- DWI (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Design (1)
- Diabetes mellitus (1)
- EAHP/SH bone marrow workshop (1)
- EBER in situ hybridization (1)
- EBV (1)
- EGF (1)
- ERM proteins (1)
- EZH1 (1)
- EZH2 (1)
- Epidemiological study (1)
- Epigenese (1)
- Epigenetics (1)
- Epigenetik (1)
- Epitope (1)
- Epstein-Barr virus (1)
- Extraocular eye muscles (1)
- F-19 MRI (1)
- FADD (1)
- FARS1 (1)
- FDG PET/CT (1)
- FFPE (1)
- FGF-pathway (1)
- FINCA (1)
- FLT-PET (1)
- FTIR spectroscopy (1)
- Factor receptor (1)
- Fibrin glue (1)
- Forskolin (1)
- Frequency (1)
- GABP (1)
- GFAP (1)
- GIST (1)
- GLP-1 (1)
- GSH (1)
- Gallium (1)
- Gen-Anordnung (1)
- Gene (1)
- Gene-expression (1)
- Genexpression (1)
- Genitoanal region (1)
- Genome wide analysis (1)
- Genregulation (1)
- Glioma stem cells (1)
- Graft-versus-host-disease (1)
- GvHD (1)
- H3K27me3 (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HNSC (1)
- HSC (1)
- Hans algorithm (1)
- Head (1)
- Head and neck cancers (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- Hsp90 (1)
- Hypercortisolism (1)
- IDH (1)
- IDH1/2 (1)
- IFN (1)
- IFN-γ (1)
- IGF1R (1)
- IL-10 (1)
- IL-17 (1)
- IL-2 (1)
- IL-5 (1)
- IR (1)
- IRF4 (1)
- Ibrutinib (1)
- Images (1)
- Immunisierung (1)
- Immunoreceptors (1)
- Immunosuppression (1)
- Immunotherapy (1)
- Immunrezeptoren (1)
- Immunsystem (1)
- In-vivo (1)
- Inflammation (1)
- Intestinal Intraepithelial Lymphocy (1)
- Iron-oxide (1)
- Irradiation (1)
- JUN (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kaposi sarcoma (1)
- Keimzentrum (1)
- Keimzentrumsreaktion (1)
- Kidney cancer (1)
- Killerzelle (1)
- Klonalitaetsanalysen (1)
- Krebs (1)
- Krebs <Medizin> (1)
- LESA (1)
- LITAF (1)
- Lateral suboccipital craniectomy (1)
- Lesions (1)
- Ligand (1)
- Lipom (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- Lymphocytes (1)
- Lymphomas (1)
- Lymphome (1)
- Lymphozyt (1)
- MDS (1)
- MEK/ERK-signaling (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MITF-low (1)
- MIZ1 (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- Malignancies (1)
- Mantle cell lymphoma (1)
- Maschinelles Lernen (1)
- Medical research (1)
- Mensch (1)
- Merlin (1)
- Metastases (1)
- Methylation (1)
- Methylierung (1)
- Molecular pathogenesis (1)
- Molekularbiologie (1)
- Molekulargenetik (1)
- Muskelzelle (1)
- Myb-MuvB (1)
- Myeloma cells (1)
- Myelomas (1)
- Mykose (1)
- NEC (1)
- NET (1)
- NF-KAPPA-B (1)
- NF-\(\kappa\)B pathway (1)
- NF-κB (1)
- NFATc (1)
- NFATc1 sumoylation (1)
- NFATc1/αA (1)
- NFATs (1)
- NFE2L2 (1)
- NGS (1)
- NHLRC2 (1)
- NIH-3T3 (1)
- NLPHL (1)
- NR3C1 (1)
- Nestin (1)
- Nicotinischer Acetylcholinrezeptor (1)
- Nodo-parandopathy (1)
- Non Hodgkin Lymphoma (1)
- Non Hodgkin Lymphome (1)
- Nrf2 (1)
- Nuclear expression (1)
- OBF-1 OCA-B (1)
- OCT-1-deficient mice (1)
- OncotypeDX\(^{®}\) (1)
- Organoids (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAI-1 (1)
- PCDHGC3 (1)
- PCI-32765 (1)
- PD-L1 (1)
- PI3K (1)
- PKA (1)
- PLAG1 rearrangement (1)
- PRRT (1)
- PTEN (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathway (1)
- Pentixafor (1)
- Plasmozytom (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Posttranskriptionelle Regulation (1)
- Pou2af1 (1)
- Profiling (1)
- Prognose (1)
- Prognosis (1)
- Promoter (1)
- Promotor <Genetik> (1)
- R-CHOP (1)
- RCC (1)
- RNA Expression (1)
- RNA probe (1)
- RNA-Sequenzierung (1)
- RNAPOL1 (1)
- RNAScope (1)
- RYGB (1)
- Random Forest (1)
- Rats (1)
- Receptor-Tyrosine Kinases (1)
- Regulatorgen (1)
- Regulatory-cells (1)
- Renal cell carcinoma (1)
- Rezeptor-Tyrosinkinasen (1)
- Rheumatoid arthritis (1)
- Rheumatoide Arthritis (1)
- Rho-GTPases (1)
- Richter's syndrome (1)
- Richter-Syndrom (1)
- Rituximab plus (1)
- Riutximab (1)
- SARS-CoV-2 (1)
- SB332235 (1)
- SGN-35 (1)
- SLC7A11 (1)
- SOAT1 (1)
- SSTR (1)
- Sequenzdaten (1)
- Signaltransduktion (1)
- Soft-tissue infection (1)
- Sox9 (1)
- SphK1 (1)
- Spinal dissemination (1)
- Spindle cell (1)
- Spleen (1)
- Sprue (1)
- Starry Sky (1)
- Sunitinib (1)
- Suppression (1)
- Surgery (1)
- Survival (1)
- Synovialmembran (1)
- T cell differentiation (1)
- T cell receptors (1)
- T lymphocyte (1)
- T(H)17 cells (1)
- T-Zellen (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell transfer (1)
- T-cells (1)
- T-follicular regulatory cell (1)
- TCR signaling cascade (1)
- TGF-alpha (1)
- TP53 (1)
- TP53 mutations (1)
- TTK (1)
- T\(_{reg}\) and Foxp3 (1)
- Targeted Therapies (1)
- Targets (1)
- Temozolomide (1)
- Th (1)
- Th17 (1)
- Thymocytes (1)
- Tlymphozyten (1)
- Tracking (1)
- Transcription factors (1)
- Transcription-factor (1)
- Transkriptionfaktoren (1)
- Translational research (1)
- Tregs (1)
- Tumor (1)
- Tumor Microenvironment (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-necrosis-factor (1)
- Tumour markers (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- USP8 (1)
- USP9X (1)
- Usage (1)
- Uveitis (1)
- VDR (1)
- Vorhersage (1)
- WNT signaling (1)
- WTAP (1)
- Waldeyer’s tonsillar ring (1)
- Wilms tumour (1)
- XIAP (1)
- YAP (1)
- Zellmigration (1)
- Zellzyklus (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- abdominal lymph node metastases (1)
- abnormalities (1)
- actin (1)
- actin filament (1)
- actin filaments (1)
- activation (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute lymphoblastic leukemia (1)
- acute lymphocytic leukaemia (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adenomas (1)
- adenosine kinase (1)
- adhesion (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical (1)
- adrenocortical cancer (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- affinity (1)
- aggressive B‐cell lymphoma (1)
- allergy (1)
- allografts (1)
- alternative splicing (1)
- aluminum granuloma (1)
- aminoacyl‐tRNA synthetases (1)
- amplifications (1)
- amyloidoma (1)
- amyloidosis (1)
- anaplasia (1)
- anaplastic large cell lymphoma (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- annecin-V (1)
- anti-CD30 drug conjugate (1)
- antibodies (1)
- antigen loss (1)
- antigens (1)
- antioxidant function (1)
- aortic adventitia (1)
- apoptosis, Myc (1)
- arteriovenous loop (1)
- atopic dermatitis (1)
- atrial natriuretic peptide (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autoantibodies (1)
- autoantibody (1)
- autoantigen (1)
- autoimmune disease (1)
- autologous transplantation (1)
- autophagy (1)
- axonally transported proteins (1)
- azacitidine (1)
- bacterial toxins (1)
- behavior (1)
- benige tumor (1)
- binding (1)
- binding proteins (1)
- biofluid (1)
- bioinformatic clustering (1)
- biological sciences (1)
- biomarker prediction (1)
- biosynthesis (1)
- blood–brain barrier (1)
- bone disease (1)
- bone marrow biopsy (1)
- bone marrow cells (1)
- bone marrow–spleen–liver large B‐cell lymphoma (1)
- bone metastasis (1)
- boolean in silico models (1)
- botulinum C2 toxin (1)
- buparlisib (1)
- c-MYC (1)
- c-myc (1)
- cAMP (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac transplantation (1)
- cardiomyocyte proliferation (1)
- cartilage oligomeric matrix protein (1)
- caspase-3 (1)
- catenin (1)
- caveolin-1 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- cellular uptake (1)
- cerebellum (1)
- cerebral cortex (1)
- cerebropulmonary disease (1)
- cetuximab (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemokine receptor-4 (1)
- childhood interstitial lung disease (1)
- children (1)
- children´s interstitial lung disease (chILD) lipoid pneumonia (1)
- cholesterol pneumonia (1)
- cholesterol pneumonitis (1)
- chromatin (1)
- chromosomal aberration (1)
- chromosomes (1)
- chronic lymphocytic leukemia (1)
- chronische B-Zell Leukaemie (1)
- chronophin (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- cleavage (1)
- clostridium botulinum (1)
- coactivator OBF-1 (1)
- coated vesicles (1)
- cofilin (1)
- combined immunodeficiency (1)
- combined therapy (1)
- comparative genomic hybridization (1)
- complement system (1)
- complex (1)
- confocal Raman imaging (1)
- consensus DNA (1)
- cross-priming (1)
- cutaneous T-cell-lymphoma (1)
- cycle (1)
- cyclophsophamide (1)
- cyclosporine A (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deformation (1)
- deletions (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- diffuse large B‐cell lymphoma (1)
- disease (1)
- distinct (1)
- down regulation (1)
- drug abuse (1)
- drug resistance (1)
- drug therapy (1)
- early breast cancer (1)
- echocardiography (1)
- ectopic lymphoid follicle (1)
- ejection fraction (1)
- embryonic lethality (1)
- encephalitis lethargica (1)
- enhancer (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelial markers (1)
- epithelium (1)
- extramedullary disease (1)
- features (1)
- ferroptosis (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorescence in situ hybridisation (1)
- follicular T helper cells (1)
- follicular lymphoma (1)
- follicular regulatory T cell (1)
- follikuläre regulatorische T-Zelle (1)
- forecasting (1)
- formalin (1)
- functional characterization (1)
- fungal infection (1)
- gRNA-only (1)
- gastric bypass (1)
- gastrointestinal infections (1)
- gefitinib (1)
- genetic loci (1)
- genomic aberrations (1)
- germinal center formation (1)
- germline mutation (1)
- gesolin function (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid excess (1)
- glutaminase inhibition (1)
- goldfish optic nerve (1)
- grade 3B (1)
- group 3 (1)
- growth (1)
- growth pattern (1)
- growth patterns (1)
- growth-associated protein (1)
- gut–liver axis (1)
- head and neck cancer (1)
- heart (1)
- heart failure (1)
- helper T cells (1)
- helper T-cells (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- hemophagocytosis (1)
- hepcidin (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- high-risk Prostate Cancer (1)
- high‐grade B‐cell lymphoma (1)
- hippocampal stem cells (1)
- hnRNP K (1)
- hormones (1)
- human (1)
- human brain (1)
- human cerebral endothelial cells (1)
- human genome (1)
- humoral immunity (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hypercortisolism (1)
- iiron transporter (1)
- immune cells (1)
- immune check inhibitor (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune evasion (1)
- immune infiltration (1)
- immune system (1)
- immunity (1)
- immunocytochemistry (1)
- immunofuorescence double staining (1)
- immunoglobulin promoters (1)
- immunology and microbiology section (1)
- immunotherapeutics (1)
- immunotherapy (1)
- in silico analysis (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- induction (1)
- inflammation-induced tissue demage (1)
- integrated stress response (1)
- integrin (1)
- interleukin-8 (1)
- interleukins (1)
- intestine (1)
- intraosseous (1)
- intravascular large B‐cell lymphoma (1)
- invasion (1)
- involvement (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- karyotype (1)
- kidney cancer (1)
- kinase (1)
- kinases (1)
- kinetic mechanism (1)
- knock down (1)
- large cell transformation (1)
- latency type (1)
- lesions (1)
- leukemia (1)
- lichen planus (1)
- lineage (1)
- lineage differentiation (1)
- lipid droplets (1)
- lipids (1)
- lipoblastoma (1)
- lipoid pneumonitis (1)
- liquid biopsy (1)
- liraglutide (1)
- livin (1)
- lung fibrosis (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte (1)
- lymphocyte activation (1)
- lymphocyte differentiation (1)
- lymphocytes (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphoid-tissue (1)
- lymphoid-tissue lymphomas (1)
- mRNA expression (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malt lymphoma (1)
- mammalian cells (1)
- mandible (1)
- mantel cell lymphoma (1)
- mantle cell lymphoma (1)
- marcophages (1)
- marrow transplantation (1)
- mass cytometry (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- medical research (1)
- medicine (1)
- membrane topology (1)
- membrane translocation (1)
- memory B cells (1)
- meningeal inflammation (1)
- mesenchymal markers (1)
- mesenteric lymph node (1)
- mesentery (1)
- messenger-RNA transport (1)
- metabolism (1)
- metagenomics (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- microRNA-221 (1)
- microglia (1)
- microvessel permeability (1)
- mitochondrial DNA (1)
- mitosis (1)
- mitotane (1)
- mitotic genes (1)
- molecular subtypes (1)
- monoclonal antibody (1)
- mouse model (1)
- mtDNA (1)
- multifocal growth (1)
- multigene-array (1)
- multiple sclerosis (1)
- multivariate data analysis (1)
- multi‐organ disease (1)
- murine homolog (1)
- mutant p53 (1)
- mutation (1)
- mutational targeting (1)
- myasthenia (1)
- myasthenia gravis (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- nephroblastoma (1)
- nervous system (1)
- network (1)
- neurodegeneration (1)
- neurodegenerative disease (1)
- neuroendocrine tumor (1)
- neuromelanin (1)
- neurooncology (1)
- neuropathology (1)
- neuroscience (1)
- neurotoxicity (1)
- neurovascular unit (1)
- neutral loss (1)
- next generation sequencing (1)
- niche (1)
- nicotinic acetylcholine receptor (1)
- nodular lymphcyte (1)
- non-small cell lung cancer (1)
- noncoding RNAs (1)
- normal adrenal glands (1)
- notch signaling (1)
- obinutuzumab (1)
- olfactory bulb (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- oxidative stress (1)
- p53 (1)
- p53 expression (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pFADD (1)
- pan-RCC (1)
- pancreatic cancer (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- parathyroid carcinoma (1)
- parkinson’s disease (1)
- pathogenesis (1)
- pathology (1)
- pathway (1)
- patient access (1)
- patient survival (1)
- pediatric (1)
- pediatric lymphoma (1)
- pembrolizumab (1)
- peptide receptor radionuclide therapy (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- peripheral T-cell (1)
- phosphatase 2A (1)
- phospholipase A(2) (1)
- plasmablasts (1)
- pleural mesothelioma (1)
- postencephalitic parkinsonism (1)
- precision oncology (1)
- prediction (1)
- primary bone marrow presentation (1)
- primary cell culture (1)
- primary cutaneous follicular B-cell lymphoma (1)
- prognostic factor (1)
- prognostic marker (1)
- prognostic value (1)
- progressive multiple sclerosis (1)
- prostate cancer (1)
- protein and mRNA expression (1)
- proteins (1)
- pseudocarcinomatous hyperplasia (1)
- pseudolymphoma (1)
- psoas muscle (1)
- psoriasis (1)
- radiation (1)
- radiation-induced migration (1)
- radiotherapy (1)
- rag (1)
- raman spectroscopy (1)
- rare SNP (1)
- real world data (1)
- recurrence-free survival (1)
- refractory/relapsed lymphoma (1)
- regional development (1)
- regulatory T cells (1)
- regulatory T-cells (1)
- renal cancer (1)
- renal cell carcinoma (1)
- repeated surgery (1)
- resistance (1)
- restoration (1)
- retroperitoneal tumor (1)
- reverse transcriptase-polymerase chain reaction (1)
- rheumatoid arthritis (1)
- rheumatoiden Arthritis (1)
- ribosome (1)
- ribosyltransferase (1)
- roquin (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- scoring system (1)
- seminoma (1)
- senescence (1)
- serum (1)
- signal transduction (1)
- slice culture (1)
- somatic hypermutation (1)
- somatic mutations (1)
- spinal-cord-injury (1)
- splice variant (1)
- squamous tumors (1)
- stem cell transplantation (1)
- stem-cells (1)
- stemness (1)
- subventricular zone (1)
- suppression (1)
- suppressor (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical treatment (1)
- systemic sclerosis (1)
- t cells (1)
- t-SNE (1)
- target (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- targeted therapy (1)
- tauopathy (1)
- tetraspanin (1)
- tetraspanin protein (1)
- theranostics (1)
- therapeutic target (1)
- therapy response (1)
- thiol starvation (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymocytes (1)
- thymoma (1)
- tissue preparation (1)
- transcript (1)
- transcription factor FOXP1 (1)
- transcription factors (1)
- transcriptional repression (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transformation (1)
- translocation (1)
- transplantation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- treg cells (1)
- triple-negative breast cancer (1)
- tumor heterogeneity (1)
- tumor immunology (1)
- tumor slice cultures (1)
- tumor spheroids (1)
- tumor vaccination (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- tumour heterogeneity (1)
- tyrosine kinase inhibitor (TKI) (1)
- uPA (1)
- ubiquitin (1)
- unsupervised clustering (1)
- up regulation (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- vemurafenib (1)
- venetoclax (1)
- virus–iron interaction (1)
- visual clustering (1)
- vitamin D receptor (1)
- vitamin metabolism (1)
- von Economo (1)
- whole-exome sequencing (1)
- ɑ-Synuclein and iron (1)
- α-synuclein-specific T cells (1)
Institute
- Pathologisches Institut (207) (remove)
Schriftenreihe
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
The cystine/glutamate antiporter xCT is an important source of cysteine for cancer cells. Once taken up, cystine is reduced to cysteine and serves as a building block for the synthesis of glutathione, which efficiently protects cells from oxidative damage and prevents ferroptosis. As melanomas are particularly exposed to several sources of oxidative stress, we investigated the biological role of cysteine and glutathione supply by xCT in melanoma. xCT activity was abolished by genetic depletion in the Tyr::CreER; Braf\(^{CA}\); Pten\(^{lox/+}\) melanoma model and by acute cystine withdrawal in melanoma cell lines. Both interventions profoundly impacted melanoma glutathione levels, but they were surprisingly well tolerated by murine melanomas in vivo and by most human melanoma cell lines in vitro. RNA sequencing of human melanoma cells revealed a strong adaptive upregulation of NRF2 and ATF4 pathways, which orchestrated the compensatory upregulation of genes involved in antioxidant defence and de novo cysteine biosynthesis. In addition, the joint activation of ATF4 and NRF2 triggered a phenotypic switch characterized by a reduction of differentiation genes and induction of pro-invasive features, which was also observed after erastin treatment or the inhibition of glutathione synthesis. NRF2 alone was capable of inducing the phenotypic switch in a transient manner. Together, our data show that cystine or glutathione levels regulate the phenotypic plasticity of melanoma cells by elevating ATF4 and NRF2.
Machine-Learning-Based Identification of Tumor Entities, Tumor Subgroups, and Therapy Options
(2023)
Molecular genetic analyses, such as mutation analyses, are becoming increasingly important in the tumor field, especially in the context of therapy stratification. The identification of the underlying tumor entity is crucial, but can sometimes be difficult, for example in the case of metastases or the so-called Cancer of Unknown Primary (CUP) syndrome. In recent years, methylome and transcriptome utilizing machine learning (ML) approaches have been developed to enable fast and reliable tumor and tumor subtype identification. However, so far only methylome analysis have become widely used in routine diagnostics.
The present work addresses the utility of publicly available RNA-sequencing data to determine the underlying tumor entity, possible subgroups, and potential therapy options. Identification of these by ML - in particular random forest (RF) models - was the first task. The results with test accuracies of up to 99% provided new, previously unknown insights into the trained models and the corresponding entity prediction. Reducing the input data to the top 100 mRNA transcripts resulted in a minimal loss of prediction quality and could potentially enable application in clinical or real-world settings.
By introducing the ratios of these top 100 genes to each other as a new database for RF models, a novel method was developed enabling the use of trained RF models on data from other sources.
Further analysis of the transcriptomic differences of metastatic samples by visual clustering showed that there were no differences specific for the site of metastasis. Similarly, no distinct clusters were detectable when investigating primary tumors and metastases of cutaneous skin melanoma (SKCM).
Subsequently, more than half of the validation datasets had a prediction accuracy of at least 80%, with many datasets even achieving a prediction accuracy of – or close to – 100%.
To investigate the applicability of the used methods for subgroup identification, the TCGA-KIPAN dataset, consisting of the three major kidney cancer subgroups, was used. The results revealed a new, previously unknown subgroup consisting of all histopathological groups with clinically relevant characteristics, such as significantly different survival. Based on significant differences in gene expression, potential therapeutic options of the identified subgroup could be proposed.
Concludingly, in exploring the potential applicability of RNA-sequencing data as a basis for therapy prediction, it was shown that this type of data is suitable to predict entities as well as subgroups with high accuracy. Clinical relevance was also demonstrated for a novel subgroup in renal cell carcinoma. The reduction of the number of genes required for entity prediction to 100 genes, enables panel sequencing and thus demonstrates potential applicability in a real-life setting.
Purpose
Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody–drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease.
Methods
This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated.
Results
In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6% in the triple-negative subgroup (p < 0.000). In the cohort of the first relapse, HER2-low represented 64.1% of HR-positive vs. 48.2% of the triple-negative cohort (p = 0.03). In patients with secondary metastases, HER2-low was 75.6% vs. 50% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion.
Conclusion
HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important.
Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.
Due to the wide variety of benign and malignant salivary gland tumors, classification and malignant behavior determination based on histomorphological criteria can be difficult and sometimes impossible. Spectroscopical procedures can acquire molecular biological information without destroying the tissue within the measurement processes. Since several tissue preparation procedures exist, our study investigated the impact of these preparations on the chemical composition of healthy and tumorous salivary gland tissue by Fourier-transform infrared (FTIR) microspectroscopy. Sequential tissue cross-sections were prepared from native, formalin-fixed and formalin-fixed paraffin-embedded (FFPE) tissue and analyzed. The FFPE cross-sections were dewaxed and remeasured. By using principal component analysis (PCA) combined with a discriminant analysis (DA), robust models for the distinction of sample preparations were built individually for each parotid tissue type. As a result, the PCA-DA model evaluation showed a high similarity between native and formalin-fixed tissues based on their chemical composition. Thus, formalin-fixed tissues are highly representative of the native samples and facilitate a transfer from scientific laboratory analysis into the clinical routine due to their robust nature. Furthermore, the dewaxing of the cross-sections entails the loss of molecular information. Our study successfully demonstrated how FTIR microspectroscopy can be used as a powerful tool within existing clinical workflows.
Allogenic hematopoietic stem cell transplantation (allo-HCT) is a curative therapy for the treatment of malignant and non-malignant bone marrow diseases. The major complication of this treatment is a highly inflammatory reaction known as Graft-versus-Host Disease (GvHD). Cyclosporin A (CsA) and tacrolimus are used to treat GvHD which limits inflammation but also interferes with the anticipated Graft-versus-Leukemia (GvL) effect. These drugs repress conventional T cells (Tcon) along with regulatory T cells (Treg), which are important for both limiting GvHD and supporting GvL. Both of these drugs inhibit calcineurin (CN), which dephosphorylates and activates the nuclear factor of activated T-cells (NFAT) family of transcription factors. Here, we make use of our Cd4cre.Cas9+ mice and developed a highly efficient non-viral CRISPR/Cas9 gene editing method by gRNA-only nucleofection. Utilizing this technique, we demonstrated that unstimulated mouse T cells upon NFATc1 or NFATc2 ablation ameliorated GvHD in a major mismatch mouse model. However, in vitro pre-stimulated mouse T cells could not achieve long-term protection from GvHD upon NFAT single-deficiency. This highlights the necessity of gene editing and transferring unstimulated human T cells during allo-HCT. Indeed, we established a highly efficient ribonucleoprotein (RNP)-mediated CRISPR/Cas9 gene editing for NFATC1 and/or NFATC2 in pre-stimulated as well as unstimulated primary human T cells. In contrast to mouse T cells, not NFATC1 but NFATC2 deficiency in human T cells predominantly affected proinflammatory cytokine production. However, either NFAT single-knockout kept cytotoxicity of human CD3+ T cells untouched against tumor cells in vitro. Furthermore, mouse and human Treg were unaffected upon the loss of a single NFAT member. Lastly, NFATC1 or NFATC2-deficient anti-CD19 CAR T cells, generated with our non-viral ‘one-step nucleofection’ method validated our observations in mouse and human T cells. Proinflammatory cytokine production was majorly dependent on NFATC2 expression, whereas, in vitro cytotoxicity against CD19+ tumor cells was undisturbed in the absence of either of the NFAT members. Our findings emphasize that NFAT single-deficiency in donor T cells is superior to CN-inhibitors as therapy during allo-HCT to prevent GvHD while preserving GvL in patients.
(1) Background: C-X-C Motif Chemokine Receptor 4 (CXCR4) and Fibroblast Activation Protein Alpha (FAP) are promising theranostic targets. However, it is unclear whether CXCR4 and FAP positivity mark distinct microenvironments, especially in solid tumors. (2) Methods: Using Random Forest (RF) analysis, we searched for entity-independent mRNA and microRNA signatures related to CXCR4 and FAP overexpression in our pan-cancer cohort from The Cancer Genome Atlas (TCGA) database — representing n = 9242 specimens from 29 tumor entities. CXCR4- and FAP-positive samples were assessed via StringDB cluster analysis, EnrichR, Metascape, and Gene Set Enrichment Analysis (GSEA). Findings were validated via correlation analyses in n = 1541 tumor samples. TIMER2.0 analyzed the association of CXCR4 / FAP expression and infiltration levels of immune-related cells. (3) Results: We identified entity-independent CXCR4 and FAP gene signatures representative for the majority of solid cancers. While CXCR4 positivity marked an immune-related microenvironment, FAP overexpression highlighted an angiogenesis-associated niche. TIMER2.0 analysis confirmed characteristic infiltration levels of CD8+ cells for CXCR4-positive tumors and endothelial cells for FAP-positive tumors. (4) Conclusions: CXCR4- and FAP-directed PET imaging could provide a non-invasive decision aid for entity-agnostic treatment of microenvironment in solid malignancies. Moreover, this machine learning workflow can easily be transferred towards other theranostic targets.
The metastatic suppressor BRMS1 interacts with critical steps of the metastatic cascade in many cancer entities. As gliomas rarely metastasize, BRMS1 has mainly been neglected in glioma research. However, its interaction partners, such as NFκB, VEGF, or MMPs, are old acquaintances in neurooncology. The steps regulated by BRMS1, such as invasion, migration, and apoptosis, are commonly dysregulated in gliomas. Therefore, BRMS1 shows potential as a regulator of glioma behavior. By bioinformatic analysis, in addition to our cohort of 118 specimens, we determined BRMS1 mRNA and protein expression as well as its correlation with the clinical course in astrocytomas IDH mutant, CNS WHO grade 2/3, and glioblastoma IDH wild-type, CNS WHO grade 4. Interestingly, we found BRMS1 protein expression to be significantly decreased in the aforementioned gliomas, while BRMS1 mRNA appeared to be overexpressed throughout. This dysregulation was independent of patients’ characteristics or survival. The protein and mRNA expression differences cannot be finally explained at this stage. However, they suggest a post-transcriptional dysregulation that has been previously described in other cancer entities. Our analyses present the first data on BRMS1 expression in gliomas that can provide a starting point for further investigations.
While glioblastoma (GBM) is still challenging to treat, novel immunotherapeutic approaches have shown promising effects in preclinical settings. However, their clinical breakthrough is hampered by complex interactions of GBM with the tumor microenvironment (TME). Here, we present an analysis of TME composition in a patient-derived organoid model (PDO) as well as in organotypic slice cultures (OSC). To obtain a more realistic model for immunotherapeutic testing, we introduce an enhanced PDO model. We manufactured PDOs and OSCs from fresh tissue of GBM patients and analyzed the TME. Enhanced PDOs (ePDOs) were obtained via co-culture with PBMCs (peripheral blood mononuclear cells) and compared to normal PDOs (nPDOs) and PT (primary tissue). At first, we showed that TME was not sustained in PDOs after a short time of culture. In contrast, TME was largely maintained in OSCs. Unfortunately, OSCs can only be cultured for up to 9 days. Thus, we enhanced the TME in PDOs by co-culturing PDOs and PBMCs from healthy donors. These cellular TME patterns could be preserved until day 21. The ePDO approach could mirror the interaction of GBM, TME and immunotherapeutic agents and may consequently represent a realistic model for individual immunotherapeutic drug testing in the future.
Diagnosing any of the more than 30 types of T-cell lymphomas is considered a challenging task for many pathologists and currently requires morphological expertise as well as the integration of clinical data, immunophenotype, flow cytometry and clonality analyses. Even considering all available information, some margin of doubt might remain using the current diagnostic procedures. In recent times, the genetic landscape of most T-cell lymphomas has been elucidated, showing a number of diagnostically relevant mutations. In addition, recent data indicate that some of these genetic alterations might bear prognostic and predictive value. Extensive genetic analyses, such as whole exome or large panel sequencing are still expensive and time consuming, therefore limiting their application in routine diagnostic. We therefore devoted our effort to develop a lean approach for genetic analysis of T-cell lymphomas, focusing on maximum efficiency rather than exhaustively covering all possible targets. Here we report the results generated with our small amplicon-based panel that could be used routinely on paraffin-embedded and even decalcified samples, on a single sample basis in parallel with other NGS-panels used in our routine diagnostic lab, in a relatively short time and with limited costs. We tested 128 available samples from two German reference centers as part of our routine work up (among which 116 T-cell lymphomas), which is the largest routine diagnostic series reported to date. Our results showed that this assay had a very high rate of technical success (97%) and could detect mutations in the majority (79%) of tested T-cell lymphoma samples.